Investigating how diabetes and amyloid beta peptides affect insulin delivery to the brain
Amyloid beta peptides and type-2 diabetes sequelae synergistically inhibit insulin signaling and trafficking at the blood brain barrier
This study is looking at how type-2 diabetes and certain proteins related to Alzheimer's disease affect insulin in the brain, with the hope of finding new ways to help improve brain health for people dealing with both conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11031434 on NIH RePORTER |
What this research studies
This research explores the interaction between type-2 diabetes and amyloid beta peptides, which are linked to Alzheimer's disease. It aims to understand how these factors disrupt insulin signaling and delivery in the brain, potentially leading to increased insulin resistance. By examining the cellular and molecular mechanisms involved, the study seeks to identify new therapeutic strategies to improve brain health in affected individuals. Patients may benefit from insights that could lead to innovative treatments for Alzheimer's and diabetes-related cognitive decline.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults with type-2 diabetes who are at risk for or experiencing cognitive decline associated with Alzheimer's disease.
Not a fit: Patients without type-2 diabetes or those who do not exhibit symptoms of cognitive decline related to Alzheimer's may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve insulin delivery to the brain, potentially slowing the progression of Alzheimer's disease in patients with diabetes.
How similar studies have performed: Previous research has shown promising results in understanding the relationship between diabetes and Alzheimer's, suggesting that this approach could yield valuable insights.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Kandimalla, Karunya Kumar — University of Minnesota
- Study coordinator: Kandimalla, Karunya Kumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.